Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years
| Autor: | Walter W. Williams, David K. Kim, Carla L. Black, Rob Warnock, Jeffrey A. Kelman, Tamara Pilishvili |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Health (social science) Epidemiology Health Toxicology and Mutagenesis Advisory committee Advisory Committees 030231 tropical medicine Medicare Pneumococcal Infections Pneumococcal conjugate vaccine Pneumococcal Vaccines 03 medical and health sciences 0302 clinical medicine Health Information Management medicine Humans 030212 general & internal medicine Immunization Schedule Reimbursement Aged Aged 80 and over Vaccines Conjugate business.industry Vaccination General Medicine medicine.disease Pneumococcal polysaccharide vaccine United States Pneumococcal infections Pneumococcal vaccine Family medicine Practice Guidelines as Topic Immunology Centers for Disease Control and Prevention U.S business Medicaid medicine.drug |
| Zdroj: | MMWR. Morbidity and Mortality Weekly Report. 66:728-733 |
| ISSN: | 1545-861X 0149-2195 |
| Popis: | On September 19, 2014, CDC published the Advisory Committee on Immunization Practices (ACIP) recommendation for the routine use of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged ≥65 years, to be used in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) (1). This replaced the previous recommendation that adults aged ≥65 years should be vaccinated with a single dose of PPSV23. As a proxy for estimating PCV13 and PPSV23 vaccination coverage among adults aged ≥65 years before and after implementation of these revised recommendations, CDC analyzed claims for vaccination submitted for reimbursement to the Centers for Medicare & Medicaid Services (CMS). Claims from any time during a beneficiary's enrollment in Medicare Parts A (hospital insurance) and B (medical insurance) since reaching age 65 years were assessed among beneficiaries continuously enrolled in Medicare Parts A and B during annual periods from September 19, 2009, through September 18, 2016. By September 18, 2016, 43.2% of Medicare beneficiaries aged ≥65 years had claims for at least 1 dose of PPSV23 (regardless of PCV13 status), 31.5% had claims for at least 1 dose of PCV13 (regardless of PPSV23 status), and 18.3% had claims for at least 1 dose each of PCV13 and PPSV23. Claims for either type of pneumococcal vaccine were highest among beneficiaries who were older, white, or with chronic and immunocompromising medical conditions than among healthy adults. Implementation of the National Vaccine Advisory Committee's standards for adult immunization practice to assess vaccination status at every patient encounter, recommend needed vaccines, and administer vaccination or refer to a vaccinating provider might help increase pneumococcal vaccination coverage and reduce the risk for pneumonia and invasive pneumococcal disease among older adults (2). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|